223 related articles for article (PubMed ID: 31882511)
1. Eruptive Melanocytic Nevi Secondary to Encorafenib for BRAF Mutant Metastatic Colorectal Cancer.
Meneguzzo A; Lazzarotto A; Alaibac M
In Vivo; 2020; 34(1):441-445. PubMed ID: 31882511
[TBL] [Abstract][Full Text] [Related]
2. Eruptive naevi associated with encorafenib for metastatic colorectal cancer: two cases.
Alfallouji Y; Spencer A; Calonje E; Perrett CM; Watchorn R; Borysiewicz C; Hodgkinson T; Wasan H; Bunker CB; Sidwell RU
Clin Exp Dermatol; 2022 Oct; 47(10):1857-1858. PubMed ID: 35633107
[TBL] [Abstract][Full Text] [Related]
3. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
[TBL] [Abstract][Full Text] [Related]
4. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
[TBL] [Abstract][Full Text] [Related]
5. Involution of eruptive melanocytic nevi on combination BRAF and MEK inhibitor therapy.
Chen FW; Tseng D; Reddy S; Daud AI; Swetter SM
JAMA Dermatol; 2014 Nov; 150(11):1209-12. PubMed ID: 25142409
[TBL] [Abstract][Full Text] [Related]
6. Acquired Melanocytic Nevi Mimicking Acral Lentiginous Melanoma in a Patient Taking a BRAF Inhibitor.
Nazir ZH; Haliasos HC; Busam KJ; Marchetti MA; Linos K; Marghoob AA
JAMA Dermatol; 2023 Oct; 159(10):1147-1149. PubMed ID: 37672258
[TBL] [Abstract][Full Text] [Related]
7. Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic
Delord JP; Robert C; Nyakas M; McArthur GA; Kudchakar R; Mahipal A; Yamada Y; Sullivan R; Arance A; Kefford RF; Carlino MS; Hidalgo M; Gomez-Roca C; Michel D; Seroutou A; Aslanis V; Caponigro G; Stuart DD; Moutouh-de Parseval L; Demuth T; Dummer R
Clin Cancer Res; 2017 Sep; 23(18):5339-5348. PubMed ID: 28611198
[No Abstract] [Full Text] [Related]
8. Eruptive naevi in a patient treated with LGX818 for BRAF mutant metastatic melanoma.
Anforth RM; Carlos GR; Scolyer RA; Chou S; Fernandez-Peñas P
Melanoma Res; 2015 Feb; 25(1):91-4. PubMed ID: 25380183
[TBL] [Abstract][Full Text] [Related]
9. Drug-induced eruptive melanocytic nevi.
Vena GA; Fargnoli MC; Cassano N; Argenziano G
Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):293-300. PubMed ID: 27759434
[TBL] [Abstract][Full Text] [Related]
10. A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic
van Geel RMJM; Tabernero J; Elez E; Bendell JC; Spreafico A; Schuler M; Yoshino T; Delord JP; Yamada Y; Lolkema MP; Faris JE; Eskens FALM; Sharma S; Yaeger R; Lenz HJ; Wainberg ZA; Avsar E; Chatterjee A; Jaeger S; Tan E; Maharry K; Demuth T; Schellens JHM
Cancer Discov; 2017 Jun; 7(6):610-619. PubMed ID: 28363909
[TBL] [Abstract][Full Text] [Related]
11. BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression.
Mudaliar K; Tetzlaff MT; Duvic M; Ciurea A; Hymes S; Milton DR; Tsai KY; Prieto VG; Torres-Cabala CA; Curry JL
Hum Pathol; 2016 Apr; 50():79-89. PubMed ID: 26997441
[TBL] [Abstract][Full Text] [Related]
12. Darkening and eruptive nevi during treatment with erlotinib.
Hemperly S; Ermolovich T; Lountzis NI; Sheikh HA; Purcell SM
Cutis; 2019 Jul; 104(1):E19-E21. PubMed ID: 31487352
[No Abstract] [Full Text] [Related]
13. Eruptive melanocytic nevi associated with encorafenib and cetuximab combination therapy.
Mikami H; Akasaka E; Nakano H; Sawamura D
J Dermatol; 2023 May; 50(5):e173-e174. PubMed ID: 36585744
[No Abstract] [Full Text] [Related]
14. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].
Capovilla M
Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719
[TBL] [Abstract][Full Text] [Related]
15. Ponatinib-induced eruptive nevi and melanocytic proliferation.
Kim YH; Kim Y; Park TJ; Kang HY
Melanoma Res; 2022 Feb; 32(1):59-62. PubMed ID: 34939982
[TBL] [Abstract][Full Text] [Related]
16. Aged-looking skin and encorafenib: an adverse event of BRAF inhibitors.
Fernández-Sartorio C; Boada A; Chavez-Bourgeois MM; Ruiz Ares GJ; Arance AM; Manzano JL; García-Herrera A; Carrera C
Melanoma Res; 2018 Apr; 28(2):160-162. PubMed ID: 29485551
[No Abstract] [Full Text] [Related]
17. Eruptive melanocytic nevi induced by interferon for nodal metastatic melanoma: case report and review of the literature.
Salopek TG; Mahmood MN
J Cutan Med Surg; 2013; 17(6):410-3. PubMed ID: 24138978
[TBL] [Abstract][Full Text] [Related]
18. Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management.
Gogas HJ; Flaherty KT; Dummer R; Ascierto PA; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Sileni VC; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Gollerkeri A; Pickard MD; Robert C
Eur J Cancer; 2019 Sep; 119():97-106. PubMed ID: 31437754
[TBL] [Abstract][Full Text] [Related]
19. Improving classification of melanocytic nevi: Association of BRAF V600E expression with distinct histomorphologic features.
Kiuru M; Tartar DM; Qi L; Chen D; Yu L; Konia T; McPherson JD; Murphy WJ; Fung MA
J Am Acad Dermatol; 2018 Aug; 79(2):221-229. PubMed ID: 29653212
[TBL] [Abstract][Full Text] [Related]
20. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition.
Zimmer L; Hillen U; Livingstone E; Lacouture ME; Busam K; Carvajal RD; Egberts F; Hauschild A; Kashani-Sabet M; Goldinger SM; Dummer R; Long GV; McArthur G; Scherag A; Sucker A; Schadendorf D
J Clin Oncol; 2012 Jul; 30(19):2375-83. PubMed ID: 22614973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
